MiNK Therapeutics Inc. (INKT)
NASDAQ: INKT
· Real-Time Price · USD
7.60
0.20 (2.70%)
At close: May 02, 2025, 3:48 PM
7.96
4.74%
After-hours: May 02, 2025, 04:05 PM EDT
2.70% (1D)
| Bid | 7 |
| Market Cap | 30.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.78M |
| EPS (ttm) | -2.86 |
| PE Ratio (ttm) | -2.66 |
| Forward PE | -1.66 |
| Analyst | Buy |
| Ask | 8.59 |
| Volume | 1,636 |
| Avg. Volume (20D) | 18,527 |
| Open | 7.70 |
| Previous Close | 7.40 |
| Day's Range | 7.20 - 7.70 |
| 52-Week Range | 4.56 - 13.79 |
| Beta | 0.14 |
About INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was former...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 15, 2021
Employees 23
Stock Exchange NASDAQ
Ticker Symbol INKT
Website https://minktherapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for INKT stock is "Buy." The 12-month stock price forecast is $37.5, which is an increase of 393.42% from the latest price.
Stock Forecasts